São Paulo, February 2021 – Eurofarma, a Brazilian pharmaceutical multinational with operations in 20 Latin American countries, celebrates the production of 28 million units with the +Verde seal, in line with its global sustainability strategy. Specifically last year, more than 14.2 million products with this new concept were introduced to the market. Launched in 2018, +Verde is inserted in the packaging of some medicines to reduce the impact on the environment. 

One of the unique features is the internal packaging (blister, also known as primary packaging – which has direct contact with the chemical compound). Created from an unprecedented, cutting-edge initiative in the market, duly approved by Anvisa, the primary packaging can be de-contaminated by consumers at home and disposed of for selective collection. The initiative also offers more sustainable secondary packaging containing up to 30% recycled paper. On Eurofarma’s website, there is a step-by-step on how to clean the packaging (watch the video here).

Some of the medicines featuring the +Verde seal include Astro® tablets, Astro@ suspension, Azithromycin and Selene®. New drugs will be included in the initiative by the end of the year. At Momenta, a company of the Eurofarma Group, Minilax® also carries +Green seal because its packaging (tube) contains green polyethylene produced from sugarcane.

Proper Medication Disposal

In addition to the +Verde packaging, Eurofarma has forged an innovative partnership with Grupo Pão de Açúcar to promote the correct disposal of medicine waste and enable proper disposal of primary packaging, expired medicines, and sharp materials, such as needles and ampoules. The collectors are scattered around the Group’s drugstores in some Brazilian cities including São Paulo, Rio de Janeiro and Minas Gerais. 

About Eurofarma Group 
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers more than 310 products in approximately 650 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent more than 80% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with its largest industrial park in Brazil and plants in six other Latin American countries. The company employs more than 7,000 people.

Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarma | Twitter: @eurofarma
YouTube: @eurofarmalab